Search Results

6 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 17

    Evaluation of reduction in exposure to selected cigarette smoke constituents after switching to novel tobacco vapor product (NTV) use during a five-day confinement study in Japan

    TAKESHIGE Y.; YUKI D.; NAKAYA K.; FUTAMURA Y.
    Japan Tobacco Inc., Scientific Product Assessment Center, Yokohama, Kanagawa, Japan
    We recently developed a novel tobacco vapor product (NTV) that comprises a battery, a cartridge with a heater and nicotine-free liquid, and a tobacco capsule filled with tobacco blend. Vapor containing nicotine and flavor is produced by aerosol from the ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 18

    Evaluation of subjective effects and product use patterns of novel tobacco vapor product (NTV) use during a five-day confinement study in Japan

    NISHIHARA D.; YUKI D.; NAKAYA K.; TAKESHIGE Y.; FUTAMURA Y.
    Japan Tobacco Inc., Scientific Product Assessment Center, Yokohama, Kanagawa, Japan
    Some authorities have highlighted information relating to the abuse liability of tobacco products as key in reaching regulatory decisions. Although abuse liability should be assessed with multiple factors, one of the essential elements is the subjective ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 27

    Pharmacokinetics of nicotine following the controlled use of a prototype novel tobacco vapour product

    YUKI D.(1,2); SAKAGUCHI C.(1); KIKUCHI A.(1); FUTAMURA Y.(1)
    (1) Japan Tobacco Inc., R&D Group, Scientific Product Assessment Center, Yokohama, Kanagawa, Japan; (2) JT International S.A., Scientific & Regulatory Affairs, Geneva, Switzerland
    The objective of this clinical study was to investigate the pharmacokinetics of nicotine following the use of a prototype novel tobacco vapour (PNTV) product in comparison to a conventional cigarette (CC1). The study was conducted in Japanese healthy ...